Impact of prior oral anticoagulation therapies on post‐discharge outcomes after <scp>COVID</scp>‐19: Results from a global federated health network analysis — José Miguel Rivera‐Caravaca (2024) | RDL Network
Impact of prior oral anticoagulation therapies on post‐discharge outcomes after <scp>COVID</scp>‐19: Results from a global federated health network analysis
Article 2024 en
Authors
JR
José Miguel Rivera‐Caravaca
FF
Freddy Frost
FM
Francisco Marı́n
Abstract
1 min read
COVID-19 patients taking prior DOACs were associated with lower long-term mortality risk and ICH/gastrointestinal bleeding than patients not taking OAC. Compared to patients on DOACs, VKA users were associated with higher risks of mortality, ischaemic stroke/TIA/SE and ICH/gastrointestinal bleeding.
José Miguel Rivera‐Caravaca, Iván J. Núñez‐Gil, Professor Gregory Lip, Aitor Uribarri, María C. Viana‐Llamas, Adelina González, Alex F. Castro‐Mejía, Berta González, Emilio Alfonso, Juan Fortunato García Prieto, Chiara Cavallino, Bernardo Cortese, Gisela Feltes, Inmaculada Fernández‐Rozas, Jaime Signes‐Costa, Jia Huang, Marcos Garcı́a Aguado, Martino Pepe, Rodolfo Romero, Enrico Cerrato, Víctor Manuel Becerra‐Muñoz, Sergio Raposeiras‐Roubín, Francesco Santoro, Rodrigo Bagur, Luciano A. Sposato, Ibrahim El‐Battrawy, Álvaro López Masjuan, Antonio Fernández-Ortı́z, Vicente Estrada, Carlos Macaya, Francisco Marı́n
Discussion(0)
No comments yet. Be the first to comment.